ArticleAACE endocrinology and diabetes
Catatonia Induced by Lithium-Associated Hyperparathyroidism.
Article in AACE endocrinology and diabetes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Objective: This case describes a 62-year-old female who developed catatonia induced by lithium-associated hyperparathyroidism. The objective is to highlight the potential link between lithium-induced hyperparathyroidism and catatonia, emphasizing the diagnostic and management challenges. Case Report: A 62-year-old female with bipolar disorder, on intermittent lithium since 2010, was hospitalized after a fall. Laboratory results confirmed lithium-induced hyperparathyroidism. On hospital day 9, she developed symptoms and signs of catatonia, including moaning, unresponsiveness, and waxy flexibility, along with a peak serum calcium level of 12.1 mg/dL. Despite treatment with lorazepam and electroconvulsive therapy, her catatonia persisted. On day 31, lithium was discontinued, and intravenous zoledronic acid was administered. Her serum calcium dropped to 9.4 mg/dL, and by day 36, significant clinical improvement was noted. Discussion: Lithium-associated hyperparathyroidism can cause a range of symptoms, including fatigue, constipation, and nephrolithiasis. Severe cases may present with catatonia, though this is rarely reported. This case underscores the potential connection between lithium-induced hyperparathyroidism and catatonia, even with moderate hypercalcemia. Conclusion: Our case highlights the importance of recognizing and managing lithium-induced hyperparathyroidism in patients presenting with catatonia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.